UK

UK
#ABPI #Healthcare #NHS #The King's Fund #UK

UK performs poorly on adoption of new drugs, report shows

The UK spends less on medicines, has a lower adoption of new drugs and poorer health outcomes compared to other similar countries, according to a new report. The King’s Fund report, commissioned by the Association of the British Pharmaceutical Industry (ABPI), gives the UK’s NHS a… Read More

#News

VectorBuilder Edinburgh office
#AAV #Biotech hubs #Expansion #Gene delivery #UK #VectorBuilder

Viral vector provider opens new UK headquarters in Edinburgh

Gene delivery technologies company VectorBuilder has opened a new office in Edinburgh, hoping to bolster its presence in the United Kingdom. The new location is part of Edinburgh Technopole, a Pioneer Group in Midlothian Science Zone. “When it comes to published scientific research, the UK is… Read More

#News

#BioIndustry Association #Biotechnology #Clarivate #Funding #Investment #Private investment #UK

UK biotech sector raised £295 million in first quarter of 2023

The first quarter of 2023 has seen deal flow continue for UK life science and biotech companies at all stages of development, new data from the UK BioIndustry Association and Clarivate shows. As global macro-economic headwinds, suppressed public markets and political uncertainty weighed on investor confidence, venture investment remained steady,… Read More

#Business & Investment #Market Reports #News

Leukaemia
#Leukaemia #National Institute for Health and Care Excellence (NICE) #Regulatory #UK

UK regulator approves ‘significant advance’ in CLL treatment

The National Institute for Health and Care Excellence (NICE) has approved a combination of Imbruvica (ibrutinib) and venetoclax for all untreated chronic lymphocytic leukaemia (CLL) patients in England. The oral, fixed-duration combination treatment for adult CLL patients has been approved as first-line therapy and has been shown to be more… Read More

#News #Regulatory

Cancer research in laboratory
#AstraZeneca #Breast cancer #Cancer research #National Institute for Health and Care Excellence (NICE) #Oncology #Prostate cancer #The Institute of Cancer Research #UK

NICE approves olaparib for early-stage breast cancer and prostate cancer

The UK’s National Institute for Health and Clinical Excellence (NICE) has recommended that Lynparza (olaparib) can be used for NHS patients with both early-stage breast cancer and prostate cancer. Olaparib is PARP inhibitor that targets cancers linked to faulty BRCA1 or BRCA2 genes and works across many different cancer types. The… Read More

#News #Regulatory #Trending News

Macrophages
#Antibodies #Cancer research #Collaboration #Immuno-oncology #Japan #Macrophages #Oncology #Partnership #UK

Drug discovery partners from UK and Japan target macrophages

Macomics and Ono Pharmaceutical have entered a worldwide drug discovery collaboration agreement to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer. Under the terms of the agreement, Macomics will identify and characterise antibody candidates against the novel target of interest… Read More

#Cancer Research #News

Clinical trial
#ABPI #Clinical trial design #Clinical trials #MHRA #UK

Biggest overhaul of UK clinical trial regulation for 20 years

A series of new measures will be introduced by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to make it faster and easier to gain approval and run clinical trials in the UK. These changes represent the biggest overhaul in UK clinical trials regulation in… Read More

#News

Chancellor Jeremy Hunt and the Spring Budget
#Association of the British Pharmaceutical Industry #BioIndustry Association #Investment #Life sciences #MHRA #Regulatory #UK #UK budget #UK government

UK Spring Budget a ‘vote of confidence’ in UK life sciences

There was some good news for the UK life sciences sector in the government’s Spring Budget, but did it go far enough? DDW’s Diana Spencer takes a look at the industry’s reaction. There wasn’t much to write home about in the UK government’s Spring Budget, described by Bloomberg UK’s Marcus… Read More

#Business & Investment #Exclusive Content

Novo Nordisk head office
#ABPI #Association of the British Pharmaceutical Industry #Novo Nordisk #Pharmaceutical industry #UK

Novo Nordisk suspended from UK’s ABPI membership

Novo Nordisk has been suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) for two years due to serious breaches of the ABPI Code of Practice. This is the eighth occasion in the past 40 years the ABPI Board has issued such… Read More

#News

Pharmaceuticals manufacturing
#ABPI #Appointment #Association of the British Pharmaceutical Industry #New appointment #Pharmaceutical industry #UK

Susan Rienow confirmed as next President of the ABPI 

The ABPI Board has confirmed that Susan Rienow, UK Country President of Pfizer, will be the next President of the Association of the British Pharmaceutical Industry (ABPI).   Rienow was appointed as ABPI Vice-President in September 2022 and will formally take up her role as President in May… Read More

#News

UK financial markets
#BioIndustry Association #Biologics / Biotechnology #Clarivate #Investment #Market reporting #Mergers and acquisitions #Private investment #Seed funding #UK

UK biotech investment drops after bumper years

Investment in UK biotech has fallen from £4.5 billion in 2021 to just £1.8 billion in 2022, mirroring the global economic downturn impacting all sectors.  However, venture capital investment in the sector was the third-best year recorded for the UK, with £1.2 billion raised, new analysis from the UK BioIndustry… Read More

#Business & Investment #News

Growing bacteria to create CAR therapy
#Cancer research #CAR-T #Immuno-oncology #Immunotherapy #Kite Pharma #National Institute for Health and Care Excellence (NICE) #NHS England #Oncology #UK

Ground-breaking CAR-T therapy approved in UK

Hundreds of people with an aggressive form of lymphoma are set to benefit from the first personalised immunotherapy treatment to be recommended for routine use in the NHS.  Axicabtagene ciloleucel (Yescarta, Kite) is a CAR-T therapy for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal… Read More

#News #Regulatory #Trending News

Multiple myeloma
#Cancer research #Myeloma #National Institute for Health and Care Excellence (NICE) #UK

NICE recommends triplet regimen for relapsed multiple myeloma

NICE has recommended Ninlaro (ixazomib) with lenalidomide and dexamethasone as an option relapsed or refractory multiple myeloma (RRMM) in adults who have received two or three lines of therapy.  Since its launch in December 2017, ixazomib has been funded through the Cancer Drugs Fund and has been used to treat… Read More

#Cancer Research #News #Regulatory #Trending News

Protesting against health inequalities
#ABPI #Collaboration #Drug discovery #Drug innovation #NHS #Pharma #UK

NHS/industry collaboration could improve access to drugs

Collaborative working between the NHS and industry could reduce variations in uptake of innovative treatments across the UK, a joint report from NHS Confederation and ABPI argues.   Analysis from the report has shown a significant variation in access to innovative medicines for patients across the UK and… Read More

#News

#AbbVie #ABPI #Clinical trials #Eli Lilly #Life sciences #Pharmaceutical industry #Pharmaceuticals #UK #UK government

Pharma firms pull out of UK drug pricing agreement

AbbVie and Eli Lilly have left the voluntary medicines pricing agreement in protest over what they describe as “increasingly punitive revenue clawbacks”.  The companies have left the UK’s Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), a long-standing agreement between government and industry with roots going back to the… Read More

#Business & Investment #News #Trending News